Peter O'Donnell, ACT's Brussels Correspondent

The possibility of a "no-deal" Brexit scenario would have severe repercussions for clinical trials not only in the UK, but the rest of Europe as well.

Peter O'Donnell writes about the results of a public opinion survey, the latest the European drug industry's attempts to fight back against what it sees as a climate of misunderstanding.

Peter O'Donnell writes of the European Commission's recently published reports suggesting that some of the gaps were being filled in registries in the field of rare diseases.

The World Health Organization tries to find a balance with its Road Map for Access on how to best approach research and pricing in Europe.

New money is not going to solve problems when it comes to registries in Europe, Peter O'Donnell writes.

As elections near, politicians in Europe make promises to prioritize the fight against cancer.

Peter O'Donnell writes about Manfred Weber's announcement of what he called "his European Master Plan against Cancer" – with what he termed "a guarantee" for European citizens, taking political lobbying over health to a new level in Europe

After taking a long awaited step forward in a rare treatment, the impatience of European patient organizations are understandable given the slow emergence of advanced medicines. Peter O'Donnell writes there is good news for patients - just not quite as good as they may have thought.

A statement from Europe’s drug industry and Europe’s medical societies calls for a “bold vision” to ensure proper funding and coordination for translational research.

Discussions on collaborative health technology assessment have been so intense over the last year that it might be thought that Brussels is the hub for HTA action. Peter O'Donnell writes how there is plenty going on elsewhere in Europe.

Recent initiatives demonstrate that European health authorities are serious about combatting the proliferation of threats and opportunities from big data.

Europe is gradually attempting to maximize the potential of the scattered data that, if brought together, might help improve diagnosis and treatment of Europe's 30 million rare disease patients.

Reflections explored during the mid-February EFGCP conference in Brussels on making clinical research an element of better healthcare.

EMA drafted a plan for closer engagement with regulatory science in the next ten years, and it is looking for comments on its approach.

European Union faces a critical view on its pediatric drug development situation, highlighting a lack of treatment, infrastructure, reimbursement, and regulatory agreement.

All of Europe, from MEPs to WHO, aims to develop a comprehensive health policy, with a current priority on nutrition and physical activity.

Imagine you are in charge of European legislation on pharmaceuticals. Imagine you've been told to draft rules on how to conduct clinical assessments at European level to help measure the value of a medicine. What would you go for?

A new report on EU's digital health strategy also calls for closer coordination of national HTA arrangements-but both policy initiatives couldn't be more different.

Peter O’Donnell gauges the impact of FDA guidance on igniting the adaptive pathways debate in Europe.

A continued struggle for healthcare and healthcare innovation to be taken seriously by the EU.

Peter O’Donnell explores the convergence of policy and science in new vaccine R&D pursuits in Europe.

Peter O'Donnell discusses the EU's bid to improve the HTA and weighs in on a report made by Soledad Cabezón's.

Peter O’Donnell explores potential parallels of the U.S. “right-to-try” debate in Europe.

An additional light has been shone on the "right-to-try" debate in Europe by a strongly-worded statement from Belgium's feisty health minister, Maggie De Block.

Rare disease interests in Europe add more voices to push for greater backing of research incentives, infrastructure.

Of the 28 European Union member states, nine did not make an offer to host the European Medicines Agency (EMA) by the July 31 deadline-and one of them is very sorely missed, writes Peter O'Donnell.

Peter O'Donnell discusses Brexit challenges and how the life sciences industry is affected.

Peter O'Donnell discusses the interest expressed by members states to host the EMA.

Peter O’Donnell discusses the argument on whether or not European researchers should be allowed to continue using non-human primates in their research.

Peter O'Donnell discusses Estonia taking over the rotating presidency of the Council of the European Union.